Literature DB >> 27532824

ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg".

Suzanne A W Fuqua1, Yassine Rechoum1, Guowei Gu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27532824      PMCID： PMC5605796          DOI： 10.1001/jamaoncol.2016.1268

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  7 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Authors:  Isaac Garcia-Murillas; Gaia Schiavon; Britta Weigelt; Charlotte Ng; Sarah Hrebien; Rosalind J Cutts; Maggie Cheang; Peter Osin; Ashutosh Nerurkar; Iwanka Kozarewa; Javier Armisen Garrido; Mitch Dowsett; Jorge S Reis-Filho; Ian E Smith; Nicholas C Turner
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

3.  AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Authors:  Hazel M Weir; Robert H Bradbury; Mandy Lawson; Alfred A Rabow; David Buttar; Rowena J Callis; Jon O Curwen; Camila de Almeida; Peter Ballard; Michael Hulse; Craig S Donald; Lyman J L Feron; Galith Karoutchi; Philip MacFaul; Thomas Moss; Richard A Norman; Stuart E Pearson; Michael Tonge; Gareth Davies; Graeme E Walker; Zena Wilson; Rachel Rowlinson; Steve Powell; Claire Sadler; Graham Richmond; Brendon Ladd; Ermira Pazolli; Anne Marie Mazzola; Celina D'Cruz; Chris De Savi
Journal:  Cancer Res       Date:  2016-03-28       Impact factor: 12.701

4.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Authors:  Gaia Schiavon; Sarah Hrebien; Isaac Garcia-Murillas; Rosalind J Cutts; Alex Pearson; Noelia Tarazona; Kerry Fenwick; Iwanka Kozarewa; Elena Lopez-Knowles; Ricardo Ribas; Ashutosh Nerurkar; Peter Osin; Sarat Chandarlapaty; Lesley-Ann Martin; Mitch Dowsett; Ian E Smith; Nicholas C Turner
Journal:  Sci Transl Med       Date:  2015-11-11       Impact factor: 17.956

5.  ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.

Authors:  Guowei Gu; Suzanne A W Fuqua
Journal:  Clin Cancer Res       Date:  2015-12-23       Impact factor: 12.531

6.  Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Authors:  Gabriel N Hortobagyi; David Chen; Martine Piccart; Hope S Rugo; Howard A Burris; Kathleen I Pritchard; Mario Campone; Shinzaburo Noguchi; Alejandra T Perez; Ines Deleu; Mikhail Shtivelband; Norikazu Masuda; Shaker Dakhil; Ian Anderson; Douglas M Robinson; Wei He; Abhishek Garg; E Robert McDonald; Hans Bitter; Alan Huang; Tetiana Taran; Thomas Bachelot; Fabienne Lebrun; David Lebwohl; José Baselga
Journal:  J Clin Oncol       Date:  2015-10-26       Impact factor: 44.544

7.  Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

Authors:  Sarat Chandarlapaty; David Chen; Wei He; Patricia Sung; Aliaksandra Samoila; Daoqi You; Trusha Bhatt; Parul Patel; Maurizio Voi; Michael Gnant; Gabriel Hortobagyi; José Baselga; Mary Ellen Moynahan
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777
  7 in total
  2 in total

Review 1.  The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.

Authors:  Sasha M Pejerrey; Derek Dustin; Jin-Ah Kim; Guowei Gu; Yassine Rechoum; Suzanne A W Fuqua
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

2.  Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

Authors:  Yuechao Zhao; Mary J Laws; Valeria Sanabria Guillen; Yvonne Ziegler; Jian Min; Abhishek Sharma; Sung Hoon Kim; David Chu; Ben Ho Park; Steffi Oesterreich; Chengjian Mao; David J Shapiro; Kendall W Nettles; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.